Published in Medical Letter on the CDC and FDA, June 1st, 2008
"Most prostate cancer vaccine trials have demonstrated some activation of the immune system, limited clinical success, and few adverse effects. One strategy to overcome the problem of limited clinical success of vaccine therapies in prostate cancer could be strict patient selection. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.